Apeloa Pharmaceutical begins second share buyback program for 2025

Apeloa Pharmaceutical Co., Ltd. initiated its second share buyback program for 2025 on November 28, 2025, repurchasing 230,000 shares through concentrated bidding. This initial repurchase represents 0.02% of the company's total share capital. The highest price paid per share was RMB 16.00, while the lowest was RMB 15.91, totaling RMB 3,669,192 (excluding transaction fees).

The company's board of directors approved the share buyback plan on November 18, 2025. The program aims to repurchase shares using proprietary funds and bank loans, with repurchased shares intended for equity incentives or employee stock ownership plans. The maximum repurchase price is set at RMB 23 per share, with total funds allocated ranging from a minimum of RMB 180 million to a maximum of RMB 360 million.

The buyback period extends for 12 months from the date of board approval. Apeloa Pharmaceutical will continue to implement the share buyback program based on market conditions and its financial arrangements, ensuring compliance with relevant regulations and timely information disclosure.